Emerging Research in Primary Brain Tumor
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 31 July 2025 | Viewed by 113
Special Issue Editors
Interests: glioma; brain tumors; brain mapping; awake craniotomy; extent of resection
Special Issue Information
Dear Colleagues,
Despite tremendous surgical, technological, and therapeutic advances, the prognosis for most patients with malignant gliomas remains poor. Moreover, there remains no effective standard of care for recurrent disease, and even for patients with IDH-mutant lower-grade gliomas, many treatment options can significantly worsen their quality of life.
Over the past few decades, great efforts have been made to improve diagnostic accuracy and personalized treatment options. Molecular biomarkers have been investigated, and new classifications have been proposed to better account for tumor behavior. At the same time, new surgical, pharmacological, and immunological strategies have been developed to improve treatment outcomes. Nevertheless, many issues facing targeted or immunological therapy remain.
This Special Issue of Cancers will cover all aspects of neurological cancers, including original research into advanced imaging, molecular characterization, surgical approaches, current and experimental drug delivery options, and strategies to improve quality of life. Expert opinions, systematic reviews, and meta-analyses are also welcome.
Dr. Jacob S Young
Prof. Dr. Mitchel S. Berger
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- molecular biomarkers
- drug delivery
- immunotherapy
- personalized medicine
- targeted therapies
- glioma
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
